About

David J. Anderson is a professor at Harvard University who has played a central role in guiding the Biochemical Sciences Tutorial program for decades, including serving as Head Tutor from 1972-1996. His contributions are highlighted within the context of Harvard’s longstanding tutorial model, which emphasizes learning through discussion, primary literature, and mentorship rather than traditional lectures. Anderson's work has been instrumental in shaping the program's focus on fostering scientific thinking, interpreting evidence, and developing intellectual relationships between students and practicing scientists. His involvement in the program underscores his commitment to undergraduate education in the life sciences, particularly in the context of molecular and cellular biology.

Research topics

• Cancer research
• Medicine
• Biology
• Genetics
• Computer Science
• Internal medicine
• Cell biology
• Endocrinology
• Oncology
• Intensive care medicine
• Biochemistry

Selected publications

• Identification of MITF-regulated transcript isoforms of ubiquitously expressed genes

  Journal of Investigative Dermatology · 2026-02-01

  articleOpen accessSenior authorCorresponding
  PublisherOA PDFDOI

• A Tukia-type theorem for nilpotent Lie groups and quasi-isometric rigidity of solvable groups

  Advances in Mathematics · 2025-03-17

  article
  PublisherDOI

• Transparent Metals

  Materials research foundations · 2025-02-25

  book1st authorCorresponding

  There is much current interest in transparent metallic materials. These are optical materials based upon photonic band-gap structures which are created by combining films of metals and dielectrics. Transparent materials are used to produce devices having electrically variable optical properties. Such photonic devices exhibit increased speeds of operation, reduced size and increased immunity to temperature changes. The book references 202 original resources with their direct web links for in-depth reading.

  PublisherDOI

• Distinct Examples of Immunologic Analysis in Molecular and Cellular Biology: Small Nuclear Ribonucleoproteins and the T Cell Receptor

  Digital Commons - RU (Rockefeller University) · 2025-09-08

  articleOpen access1st authorCorresponding

  Since the discovery (Tan and Kunkel, 1966; Mattioli and Peichlin, 1971; Sharp, et al., 1972) of human SLE autoantibodies directed against RNA-protein complexes in eucaryotic nuclei, a great deal of interest has been generated regarding both the relationships of antibody specificities to disease and the biological roles of the recognized antigens. These antibodies are some of the many autoantibody species which have been described in systemic lupus erythematosus (SLE) as well as other rheimatic disease conditions. A common feature of many of these reactivities is the apparent nuclear localization of antigen. Study of the antibodies as well as these antigens has led to formation of a particularly unique bridge between clinical medicine and basic science questions in cellular biology and metabolism. The spectrum of diseases which present with antibodies directed against cellular constituents is vast although certain features of these conditions imply common aspects which may, furthermore, be of some diagnostic use.

  PublisherOA PDFDOI

• Tans, Bans, and Sedans: How Distance from Tanning Beds May Save Lives

  Journal of Investigative Dermatology · 2025-02-28

  articleOpen access1st authorCorresponding
  PublisherOA PDFDOI

• HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion

  Cell · 2025-12-15 · 6 citations

  articleOpen access

  T cell cytotoxicity. Inhibition of melanosome secretion in vivo significantly reduced tumor immune evasion. These findings suggest that MHC export protects melanoma from the cytotoxic effects of T cells. Our study highlights a novel immune evasion mechanism and proposes a therapeutic avenue to enhance tumor immunity.

  PublisherDOI

• Emerging Therapies for Congenital Melanocytic Nevi

  Journal of Experimental Pathology · 2025-01-01 · 1 citations

  articleOpen accessSenior author

  Congenital melanocytic nevi (CMN) are benign melanocytic neoplasms that vary in genetic drivers leading to the formation of pigmented lesions. Activation of Mitogen-Activated Protein Kinase (MAPK) pathway members through oncogenic mutations of NRAS or BRAF and more rarely by gene fusions allow expansion of nevomelanocytes to form CMN. Pre-clinical approaches to CMN therapy are expanding with the use of small-molecular inhibitors to mitogen-activated protein kinase kinase (MEK), RNA-based therapeutic approaches, and leveraging topical immunotherapy to regress nevi using in vitro and in vivo models and select case reports. Continued identification of CMN drivers combined with emerging therapeutic strategies will help improve CMN patient response and outcomes in the future.

  PublisherOA PDFDOI

• UV induces common cutaneous amyloid-like melanosomal protein aggregates

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-12-18

  articleOpen accessSenior authorCorresponding

  Misfolding of aggregation-prone proteins underpins diseases known as proteinopathies. One of these proteins, alpha-synuclein, is a component of aggregates in neurodegenerative conditions such as Parkinson's disease. The melanosomal protein PMEL, which forms physiologic amyloid scaffold structures on which melanin is organized in melanosomes, similarly ectopically accumulates in the dermis in many forms of cutaneous hyperpigmentation. Here, we demonstrate in a wide range of common clinical pigmentary disorders, as well as in primary melanocyte and mouse models examined by molecular, proteomic, and electron microscopic tools, that melanocytic alpha-synuclein is a prominent component of intracellular protein aggregates bound to similar proteins as in Parkinson's disease, as well as melanized extracellular protein deposits. Using the Real Time Quaking-Induced Conversion Assay (RT-QuIC), we demonstrate that UV induces misfolded melanosomal proteins to self-propagate, augmenting this pathology in prion-like fashion. CUT&RUN chromatin profiling and single-cell RNA-seq demonstrate that melanocytes utilize microphthalmia-associated transcription factor (MITF)-regulated autophagy to counteract protein aggregation, identifying aggregate removal as a core function of tanning. In contrast to extracellular aggregation, impaired intracellular aggregate removal contributes to melanocyte senescence, which conversely exacerbates chronic hypopigmentation and photoaging-related discoloration. These findings identify melanosomal proteinopathy as a common contributor to melanocyte dysfunction and suggest aggregate-focused management approaches.

  PublisherOA PDFDOI

• YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programs

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-09-15

  preprintOpen access

  Despite promising initial results in targeting the RAF-MEK-ERK cascade, resistance to BRAF/MEK inhibitors remains a critical challenge in nearly 50% of melanoma patients. Our study demonstrates that robust YAP1 activation in metastatic melanoma correlates with poor survival and drives transcriptional programs linked to therapeutic resistance. Mechanistically, YAP1 predominantly remodels the chromatin landscape in resistant tumors by partnering with BRD4 and TEAD, creating a permissive transcriptional state that sustains oncogenic signaling. Clinical validation in biopsies from resistant melanoma confirms elevated expression of YAP1 target genes. Furthermore, pharmacological inhibition of BRD4 or TEAD reduces YAP1-driven transcription and reactivates antitumor immunity programs. TEAD specific inhibitors (and not verteporfin which is a highly non-specific inhibitor) synergize with immune checkpoint blockade in in vivo model system by promoting increased CD8⁺ T cell infiltration and prolonged survival in the melanoma mouse model. Collectively, these findings reveal a chromatin-centric vulnerability in BRAF/MEK inhibitor-resistant melanoma and propose TEAD specific inhibitors as a promising dual strategy to overcome resistance and reinvigorate the immune response, offering a novel therapeutic avenue for patients.

  PublisherOA PDFDOI

• Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

  Journal of the American Academy of Dermatology · 2025-08-08 · 3 citations

  articleOpen access
  PublisherOA PDFDOI

Recent grants

• NIH Grant R01CA069531

  NIH · $2.0M · 2004

• MITF from control of pigmentation to melanoma risk

  NIH · $362k · 1996–2023

• MITF from control of pigmentation to melanoma risk

  NIH · $342k · 1996–2018

• Therapeutic strategies for treatment of giant congenital melanocytic nevi

  NIH · $512k · 2017–2028

• Transcriptional mechanisms and melanoma

  NIH · $2.8M · 2013–2019

Frequent coauthors

• Keith T. Flaherty

  Massachusetts General Hospital

  197 shared

• Hans R. Widlund

  Brigham and Women's Hospital

  120 shared

• Levi A. Garraway

  87 shared

• Jennifer A. Wargo

  The University of Texas MD Anderson Cancer Center

  83 shared

• Donald P. Lawrence

  82 shared

• F. Stephen Hodi

  82 shared

• Dennie T. Frederick

  Massachusetts General Hospital

  75 shared

• Jennifer A. Lo

  Massachusetts General Hospital

  71 shared

Labs

• Harvard’s Biochemical Sciences Tutorial ProgramPI